via Penn Medicine
An experimental therapy has brought prolonged remissions to a high proportion of patients who were facing death from advanced leukemia after standard treatments had failed, researchers are reporting.
The therapy involves genetically programming cells from the patient’s own immune system to fight the disease.
The research included 30 patients: five adults ages 26 to 60, and 25 children and young adults ages 5 to 22. All were severely ill, with acute lymphoblastic leukemia, and had relapsed several times or had never responded to typical therapies. In more than half, the disease had come back even after a stem-cell transplant, which usually gives patients the best hope of surviving. Their life expectancy was a few months, or in some cases just weeks.
Six months after being treated, 23 of the 30 patients were still alive, and 19 of them have remained in complete remission.
The study, by researchers at the Children’s Hospital of Philadelphia and the Hospital of the University of Pennsylvania, is being published in The New England Journal of Medicine.
“We have a number of patients who are a year or more out and are in remission and not requiring other therapies,” said Dr. Stephan A. Grupp, who led the part of the study done at Children’s Hospital of Philadelphia. He said those long remissions gave the researchers hope that the treatment would have lasting effects.
Earlier reports by the same researchers involved only a handful of patients, some with chronic rather than acute leukemia. The scientists say the growing number of patients treated helps demonstrate that the findings are real.
The Latest on: Leukemia
via Google News
The Latest on: Leukemia
- “She was everything”: North Braddock Borough, others to donate blood in honor of teen with leukemiaon May 19, 2022 at 12:24 am
Nichole went to the hospital for a headache. A few tests later would reveal the seemingly healthy girl had leukemia.
- Good News Thursday: Anonymous donor pays student debt for entire graduating class in Texas, scientists find breakthrough in leukemia treatmenton May 18, 2022 at 11:44 am
Anonymous donor pays student debt for entire graduating class in Texas, scientists find breakthrough in leukemia treatment ...
- Young leukemia survivors may have shorter life spanson May 18, 2022 at 9:54 am
Even when they're cured, teen and young adult survivors of leukemia have shorter life spans than those who've never had a blood cancer, researchers at the University of Texas MD Anderson Cancer Center ...
- New Hope for Reversing Acute Leukemia Patients’ Resistance to Treatmenton May 18, 2022 at 9:23 am
University of South Australia scientists have made a breakthrough in overcoming drug resistance in acute myeloid leukemia.
- Surviving Leukemia in Youth Can Still Mean Shorter Life Spans: Studyon May 18, 2022 at 4:44 am
By By Robert Preidt HealthDay Reporter, HealthDay Reporter WEDNESDAY, May 18, 2022 (HealthDay News) -- Leukemia at a young age is likely to affect survivors' longevity, a new study cautions. Even when ...
- Acute Myeloid Leukemia Market In 2022 : Industry Growth, Top Players, Segmentation and Forecast to 2026 with Top Countries Dataon May 16, 2022 at 10:49 pm
May 17, 2022 (The Expresswire) -- ""Acute Myeloid Leukemia Market"" Insights 2022 By Types ( Chemotherapy, Radiation Therapy, Stem Cell Transplant, ...
- Clinical Challenges: Treating TP53-Mutated Acute Myeloid Leukemiaon May 16, 2022 at 9:16 am
While advances in acute myeloid leukemia (AML) research have led to the development of a variety of novel treatments for the disease, finding optimal strategies to treat AML patients with TP53 ...
- AYA survivors of leukemia have worse long-term survival outcomes than general populationon May 16, 2022 at 9:10 am
If you continue to have this issue please contact [email protected] Back to Healio Survivors of adolescent and young-adult acute myeloid leukemia and acute lymphoblastic leukemia had lower ...
- Targeted Therapy to Treat Acute Myeloid Leukemia with FLT3 Mutation: How It Works, Side Effects, and Moreon May 16, 2022 at 3:27 am
Some people with acute myeloid leukemia (AML) have a mutation in the FLT3 gene. Targeted therapies called FLT3 inhibitors can help treat AML in people with this mutation.
- Adolescent and young adult leukemia survivors face higher mortality rates than the general population for decades after diagnosison May 13, 2022 at 12:13 am
The long-term survival of adolescent and young adult (AYA) acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) survivors was shorter than that of the general population, and the ...
via Bing News
